Founded by someone also involved in start-up of MitoSciences - itself an SBIR involved firm that in 2011 was sold to Abcam PLC - mAbDx specializes in creating novel immunodiagnostics through biomarker discovery and immunoassay development. Focused on development and deployment of immunochemical reagents and immunoassays as tools for basic and clinical research, principals of the firm have been responsible for development of hundreds of monoclonal antibodies (mAbs) used in academic researc, many of these mAbs having been licensed out by the UO for commercialization by leading biotechnology companies. At mAbDx many other research collaborations with academic and clinical partners have been established to develop and validate the utility of new mAbs and assays for basic and clinical research. Many of the mAbs and assays resulting from these collaborations have been commercialized, allowing their use by independent researchers in a wide range of published studies. Internal to mAbDx, work is organized around sveral areas: Systemic Inflammatory Response Syndrome (SIRS): Sepsis (SIRS with documented infection); Marine Shellfish Vibriosis: Head and Neck Squamous Cell Carcinoma (HNSCC) and Inherited Mitochondrial Diseases
